What are the facts?
In 1992, Hannah Bruesewitz received doses of the diphtheria–tetanus–pertussis (DTP) vaccine manufactured by Lederle Laboratories, a division later acquired by Wyeth. Within a day of one vaccination, Hannah suffered a series of seizures and was subsequently diagnosed with a residual seizure disorder and developmental delays. Her parents filed a petition in the National Vaccine Injury Compensation Program (VICP), the no-fault compensation scheme established by the National Childhood Vaccine Injury Act of 1986 (NCVIA). A special master denied compensation, concluding that Hannah's injuries were not a listed "Table Injury" and that petitioners had not proven causation-in-fact. After rejecting the VICP judgment, the Bruesewitzes sued Wyeth in Pennsylvania state court, alleging a state-law design defect—specifically that the whole-cell pertussis DTP vaccine was unreasonably dangerous when a safer, feasible alternative design (acellular DTaP) existed. Wyeth removed the case to federal court, which granted summary judgment on the ground that the NCVIA preempts design-defect claims. The Third Circuit affirmed. The Supreme Court granted certiorari to resolve whether 42 U.S.C. § 300aa-22(b)(1) bars all state-law design-defect claims against vaccine manufacturers for vaccine-related injuries.
What is the legal issue?
Does the National Childhood Vaccine Injury Act of 1986, 42 U.S.C. § 300aa-22(b)(1), preempt all state-law design-defect claims against vaccine manufacturers for vaccine-related injuries where the vaccine was properly manufactured and accompanied by proper directions and warnings?
What rule applies?
Under the NCVIA, a vaccine manufacturer is not liable in a civil action for damages arising from a vaccine-related injury or death if the injury or death resulted from side effects that were unavoidable even though the vaccine was properly prepared and accompanied by proper directions and warnings. 42 U.S.C. § 300aa-22(b)(1). The Act establishes a comprehensive no-fault compensation program (the VICP), requires claimants to proceed first through that program, and preserves only certain traditional tort claims (notably, manufacturing defect and certain failure-to-warn claims) while preempting design-defect claims.
What did the court hold?
Yes. The NCVIA preempts all state-law design-defect claims against vaccine manufacturers for vaccine-related injuries when the vaccine was properly prepared and accompanied by proper directions and warnings. The judgment for Wyeth was affirmed.
What is the reasoning?
Text and structure. The Court, in an opinion by Justice Scalia, read § 300aa-22(b)(1) to categorically bar design-defect claims. The provision states that manufacturers are not liable for injuries caused by side effects that were "unavoidable even though the vaccine was properly prepared and was accompanied by proper directions and warnings." The majority reasoned that Congress distinguished among types of product-defect theories by expressly referencing proper preparation (manufacturing) and proper directions and warnings, while omitting any comparable opening for liability based on design. That omission, coupled with the statute's reference to "unavoidable" side effects, indicates a deliberate choice to remove design-defect liability from the tort landscape for covered vaccines. Role of "unavoidable." Petitioners argued that "unavoidable" imported a case-by-case inquiry akin to Restatement (Second) of Torts § 402A, comment k, requiring proof that no safer alternative design existed. The Court rejected that view, explaining that Congress did not incorporate comment k wholesale. Rather, the Act's language and architecture treat the unavoidability of certain vaccine side effects as a general premise: some adverse events cannot be eliminated even with proper manufacturing and adequate warnings. Reading "unavoidable" to require individualized alternative-design trials would subvert the Act's carefully constructed balance and its channeling of claims through the VICP. Purpose and policy. Congress enacted the NCVIA to stabilize the vaccine supply and encourage continued innovation amid a liability crisis that threatened vaccine availability. Design-defect litigation invites juries to second-guess complex, FDA-approved tradeoffs among efficacy, broader public-health benefits, and risks. The Act's design places those tradeoffs in the hands of federal regulators ex ante, while providing swift, certain compensation to injured individuals ex post through the VICP. Allowing state juries to impose varying design standards would undermine uniformity and predictability, frustrating the Act's central purposes. Statutory coherence. The NCVIA expressly preserves certain manufacturer liability—e.g., for improper manufacture and, under delineated conditions, for inadequate warnings. By specifically enumerating these surviving claims yet saying nothing parallel about design defects, Congress signaled that design-defect claims do not survive. The Court also emphasized procedural features (mandatory resort to the VICP as a first step, limitations on attorney's fees, and the Vaccine Injury Table) that reflect an integrated remedial scheme inconsistent with broad, residual design-defect litigation. Concurring and dissenting views. Justice Breyer concurred, emphasizing legislative history and administrative materials to reach the same conclusion that design-defect suits are preempted. Justice Sotomayor, joined by Justice Ginsburg, dissented, arguing that Congress adopted comment k's individualized approach and that "unavoidable" requires case-specific proof that no feasible, safer alternative design existed. Justice Kagan took no part in the case. Bottom line. Reading the text, structure, and purpose of the NCVIA together, the Court held that Congress displaced state-law design-defect claims for covered vaccines, leaving plaintiffs to the VICP and to the Act's preserved tort theories (manufacturing defect and certain failure-to-warn claims).
Why is this case significant?
Bruesewitz is a leading case on statutory preemption in products liability and a blueprint for analyzing Congress's redesign of remedies in heavily regulated industries. For practitioners, it definitively forecloses state-law design-defect suits against vaccine manufacturers for covered vaccines, channeling claims to the Vaccine Court and to the limited tort avenues the NCVIA preserves. For students, it is a model of textualist reasoning grounded in statutory structure and purpose, and it highlights the interplay among federal regulation, tort law, and public health policy. The case also provides a useful contrast with decisions like Wyeth v. Levine, underscoring that preemption outcomes turn on statutory text and regulatory frameworks, not on a general pro- or anti-preemption posture.
What kinds of claims against vaccine manufacturers remain viable after Bruesewitz?
The NCVIA preserves claims for improper manufacture (manufacturing defects) and, under specified conditions, failure-to-warn claims, including those related to compliance or noncompliance with federal labeling requirements. However, design-defect claims—alleging that the vaccine's design itself was unreasonably dangerous—are preempted if the vaccine was properly prepared and carried proper directions and warnings.
Must a claimant use the Vaccine Injury Compensation Program before filing a civil suit?
Yes. The NCVIA requires a claimant to file first in the VICP. After a judgment or after specified time periods, the claimant may elect either to accept the VICP award or to reject it and pursue a limited civil action subject to the Act's substantive constraints, including the preemption of design-defect claims recognized in Bruesewitz.
How does this case relate to Wyeth v. Levine?
In Wyeth v. Levine, the Court declined to find preemption of a state-law failure-to-warn claim for a prescription drug, largely due to the absence of a comparable statutory preemption framework and the ability of manufacturers to unilaterally strengthen warnings. Bruesewitz is different: Congress enacted a specific, comprehensive remedial and liability-limiting scheme for vaccines, which the Court interpreted to expressly foreclose design-defect suits while preserving other limited claims.
Did the Court rely on Restatement (Second) of Torts § 402A, comment k?
The Court discussed comment k but declined to import its case-by-case alternative-design inquiry. Instead, the majority concluded that Congress crafted its own categorical approach in § 300aa-22(b)(1), treating certain vaccine side effects as unavoidably risky and channeling compensation through the VICP rather than through design-defect litigation.
What were the votes and separate opinions?
Justice Scalia wrote the majority opinion, joined by Chief Justice Roberts and Justices Kennedy, Thomas, and Alito. Justice Breyer concurred separately. Justice Sotomayor, joined by Justice Ginsburg, dissented. Justice Kagan did not participate.
Does Bruesewitz eliminate all tort liability for vaccines?
No. The decision bars design-defect claims but leaves room for claims based on manufacturing defects and certain failures to warn, consistent with the NCVIA's text. It also leaves intact the VICP, which provides a principal avenue of recovery for vaccine-related injuries without requiring proof of fault.